KRYSKrystal Biotech, Inc.Signing up patients
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Cancer · Melanoma Stage III · Melanoma Stage IV · Cutaneous Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 240 (planned)
- Started
- Oct 31, 2023
- Main results expected
- Jul 2027
- Fully finished
- Jul 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of adverse events (AEs)
Measured over: up to 36 months
Percentage of serious adverse events (SAEs)
Measured over: up to 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05970497 · record last updated 2025-05-18 · checked 2026-11-09 15:47 UTC